~" This study was undertaken to confirm the presence of alpha-l-antitrypsin (a~-AT) in human brain tumors and to attempt to elucidate its significance. Seventy-seven consecutive unselected patients with various brain tumors were entered in this study. The a~-AT and a2-macroglobulin contents of the tumor extracts were qualitatively assessed by Ouchterlony immunodiffusion techniques. Plasminogen activator (PA) activity was assayed electrophoretically on sodium dodecyl sulfate gels. The patients were divided into two groups according to the positivity of their tumors to a~-AT. Sixty-eight percent of the tumors were positive for a~-AT, and all specimens were negative for a2-macroglobulin. Clinical and biological parameters obtained in all study patients failed to show statistically significant differences between the two groups with the exception of PA activity (p = 0.001), the peritumoral edema as seen on computerized tomography, and the preoperative serum fibrinogen level. These three parameters were higher in the group with specimens positive to a~-AT.
I
N recent years, there has been rapidly increasing evidence that tumor cell proteinases play an important role in tumor invasionY In support of this theory are the many observations demonstrating the ability of tumor cells in culture to degrade extracellular proteins 32 and the findings of increased levels of proteinases capable of digesting connective tissue matrix component within the tumor environment. 21' 23"3~ High concentrations of proteinases such as plasminogen activator (PA) substance(s) were shown to be produced by cultured cells derived from brain tumors 5~ and are abundantly found in human brain tumors (R Sawaya and R Highsmith, in preparation).
As a consequence of these studies, interest has arisen in regard to the distribution of proteinase inhibitors in tumors. In a previous paper, we were able to demonstrate a proteolytic inhibitory activity associated with brain tumors. 43 Proteolytic inhibitory activity may be related to the presence of specific proteins, most of which inhibit fibrinolysis. These include alpha-l-antitrypsin (arAT), a2-antiplasmin, arantichymotrypsin, a2-macroglobulin, and antithrombin III. 8 
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We have previously postulated that al-AT was the most likely inhibitor to be associated with brain tumors. 43 This study was therefore undertaken to confirm the presence of a~-AT in human brain tumors and to attempt to elucidate the significance of its presence.
Clinical Material and Methods
Seventy-seven consecutive unselected patients (mean age _ standard error of the mean: 52.79 _ 1.8 years) with various brain tumors were entered in this study. Clinical and biological parameters were obtained on all study subjects including age, sex, duration of the symptoms, Karnofsky index, plasma fibrinogen level, prothrombin time, partial thromboplastin time, platelet count, sedimentation rate, and histological diagnosis. The tumors included benign non-neoplastic central nervous system disorders such as granulomas as well as other brain tumors such as neuroblastoma, pituitary adenoma, and lymphoma.
Computerized tomography (CT) scans were used to identify tumor volume according to the following formula: volume = ~r (a.b.c)/6 where a, b, and c represent the three axes of the tumor mass. 44 Peritumoral brain edema was defined as a low-attenuation zone surrounding the mass lesion 12 and was graded from 0 (no edema) to 5+ (marked edema) where the low-density area ex- ceeded the size of the mass lesion. Moderate edema (3+) represented a low-attenuation area equal in size to that of the mass lesion. Biopsies of tumors obtained from fresh surgical specimens during craniotomy were immediately labeled, placed on dry ice, and transferred to a -800C freezer prior to homogenization. When required for assay, tumor tissue was thawed and rapidly weighed, minced, and homogenized in 37.5 mM Tris-HCl, 0.75 mM ethylenediaminetetra-acetic acid, 75 mM NaC1, and 15 mM lysine buffer at a final pH of 9.5 in a Teflon pestle tissue homogenizer. For each specimen, 50 mg of tissue was homogenized in 1 ml of Tris buffer with 20 strokes. The al-AT and azmacroglobulin contents of the tumor extracts were qualitatively assessed by Ouchterlony immunodiffusion techniques. 31 Sheep anti-human a~-AT and sheep antihuman a2-macroglobulin and appropriate controls were obtained.* The PA activity was assayed electrophoretically on sodium dodecyl sulfate gels as described in detail elsewhere. 44 Our data were analyzed statistically by means of chisquare test, Student's t-test, and analysis of variance for a significance level of p < 0.05.
Results
The patients were separated into two groups according to the reactivity of their tumors to sheep anti-human arAT. Group I was composed of 53 patients with positive anti-arAT (68.6%), and Group II of 24 pa-* Sheep anti-human a~-antitrypsin and sheep anti-human a2-macroglobulin and appropriate controls were obtained from Behring Diagnostic, Inc., Somerville, New Jersey. t Miscellaneous = one each of: pituitary adenoma, ependymoma, sarcoid granuloma, demyelinating process, lymphoma, and adult neuroblastoma.
tients with negative anti-al-AT reactivity (31.4%). All specimens were negative for a2-macroglobulin. No statistically significant differences were observed between the two groups with regards to age, sex, Karnofsky index, duration of symptoms, size of tumor, prothrombin time, partial thromboplastin time, platelet count, and electrolyte sedimentation rate (Table 1) . Statistically significant differences were noted in the extent of the peritumoral edema on CT scans and the preoperative serum fibrinogen level in patients belonging in the positive a~-AT group. Additionally, and perhaps most importantly, PA activity was higher in tumors with positive a~-AT (p = 0.001) ( Table 1) .
Marked differences in a~-AT were noted among the various histological groups of brain tumors ( Table 2) . The difference in aI-AT reactivity reached statistical significance for the following groups: acoustic neuroma versus meningioma, metastasis versus meningioma, and acoustic neuroma versus miscellaneous brain tumors. No statistical difference in aI-AT positivity was found between malignant glioma and low-grade glioma.
Discussion
This study demonstrates that immunologically detectable aI-AT is present in both malignant and nonmalignant brain tumors. Alpha-l-antitrypsin has a broad range of enzyme inhibitory activity exceeded only by a2-macroglobulin. It is the major serine protease inhibitor of human plasma. Serine proteases represent the largest group of mammalian enzymes, and are characterized by a serine residue at their active site. 7'18'24'48 As several lines of evidence suggest that proteases may play an important role in the tumor-host relationship, maintenance of a proper balance between protease and protease inhibitors might be essential in the regulation of tumor growth. In fact, in the group of tumors with detectable a~-AT in our study, the mean value for the PA activity was significantly higher than that for the group with nondetectable arAT. It is well known that PA activity is found in a high concentration in many tumor cells, 29 and that PA activity is either at the beginning of a protease cascade or is itself the active agent. 34,39 The generation of plasmin is an important event in the breakdown of complex extracellular matrices. t9 '45 Plasminogen activator is capable of activating a latent collagenase that has long been suspected of being involved in invasion and metastasis, and is capable of promoting angiogenesis crucial to the spread and survival of the tumors. 49 Several experiments have suggested that antifibrinolytic, anticoagulant, or antiplatelet agents decrease both tumor cell survival and the incidence of successful tumor cell implantatio n. 2, 9, 15, 25, 42, 44, 47 On the other hand, the role and significance of protease inhibitors such as at-AT in tumors are not known with certainty. Local concentrations of active protease inhibitors, including at-AT, may be important in modulating tumor proteinases, and in this manner affecting the neoplastic spread. 26'4t Moreover, they can interfere with tumor promotion, perhaps by modulating the oxygen radical response. 13.17 Indeed, many synthetic and natural antiproteinases have the ability to retard tumor growth. 44 Conversely, evidence suggests that at-AT is also an important factor in the inflammatory and immune responses. It is known that at-AT plays an important role in inhibiting the cytotoxic reactions of lymphocytes including antibody-dependent cell-mediated cytotoxicity, t'37 T cell-mediated cytotoxicity, 37 and natural killer activity, l't6 It also modulates the activity of a number of inflammatory pathways controlling an excessive inflammatory response. 5 Because a rAT inhibits serine esterases released from host leukocytes 5 (some of which participate in immune cytolysis of tumor cells), the production of at-AT may compromise a vital host defense mechanism. These findings, together with the known importance of protease activities in cell functions 4'3~ and the mitogenic activity of some proteases on lymphocytes, 6 indicate the need for further investigation into the relationship of these activities to each other.
The source of at-AT in brain tumors is unknown. A number of normal tissues and cells contain at-AT, including liver, 22 histiocytes and mast cells, z2 gastrointestinal tract, It lung, 52 and pancreatic islet cells. 35 Synthesis of at-AT was reported by yolk sac, hepatocellular carcinoma, 56 certain ovarian malignancies, z~ undifferentiated liver sarcomas, ~z gastric carcinoid, 36 benign and malignant "fibrohistiocytic" tumors, 22 and osteoclastomas. 22 Akatsuka, et al., 3 using immunoelectron microscopy, have localized at-AT to the endoplasmic reticulum and Golgi apparatus of human tumors transplanted in nude mice. It is, therefore, logically possible to hypothesize that at-AT is actively produced in the region of the tumor either by the neoplastic cells or by the supportive and/or reactive cells. In support of this hypothesis is the fact that several other neoplasms have been shown to produce at-AT, especially since all somatic cells of an individual are of the same basic genetic composition. The lack of detectable a2-macroglobulin suggests that the presence of at-AT is not the result of a passive transfer from the serum. Similarly, the lack of differences in several blood parameters between the two groups is evidence against the possibility of a nonspecific acute-phase reaction. However, the higher fibrinogen level in Group I (patients positive for anti-at-AT) remains unexplained. In addition, the significant association of at-AT positivity with a higher brain edema score is of interest, since edema itself may be influenced by the local hyperfibrinolytic activity of the tumor (R Sawaya and R Highsmith, in preparation). Finally, it remains to be determined whether at-AT is the product of the tumor itself or of the reactive cells as a response to the abnormally high proteolytic activity generated by the tumor.
On the basis of the data currently available, we hypothesize that at-AT is produced primarily by tumor cells in proportion to the regional proteolytic and inflammatory activity. The role of at-AT appears to be protective to the tumor cells and immunosuppressant to the host. Additional studies will be required to further our understanding of the complex relationship that exists between proteases and protease inhibitors, and the role they play in the growth and invasiveness of the neoplastic tissue. 
